WALTHAM, Mass., July 19 /PRNewswire-FirstCall/ --
AltaRex Corp. (TSE: AXO, OTC: ALXFF.PK) announced today that Dr. Antoine
Noujaim has resigned as Chairman, Director, and Chief Scientific Officer of
the Company in order to pursue other opportunities. The Company expressed its
gratitude to Dr. Noujaim for his long service to AltaRex and wished him well
in his new endeavours.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO )
Jacques R. Lapointe, the Company's Vice-Chairman, has been appointed
Chairman, effective immediately. The Company does not intend to appoint a
Chief Scientific Officer at this time.
Additional information about AltaRex research and development, clinical
trials, news and events can be found on the Company website http://www.altarex.com.
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be forward-
looking statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to our need for capital; the risk that the
Company can not raise funds on a timely basis on satisfactory terms or at all;
the need to obtain and maintain corporate alliances, such as the alliance with
United Therapeutics, and the risk that the Company cannot establish corporate
alliances, such as the alliance in Northern Europe that the Company is
seeking, on a timely basis, on satisfactory terms, or at all; changing market
conditions; uncertainties regarding the timely and successful completion of
clinical trials and patient enrollment rates, uncertainty of pre-clinical,
retrospective, early and interim clinical trial results, which may not be
indicative of results that will be obtained in ongoing or future clinical
trials; whether the Company and/or its collaborators will file for regulatory
approval on a timely basis; uncertainties as to when, if at all, the FDA or
other regulatory authorities will accept or approve regulatory filings for the
Company's products; the need to establish and scale-up manufacturing
processes, uncertainty as to the timely development and market acceptance of
the Company's products; the risk that the claims allowed under any issued
patent owned or licensed by the Company, will not be sufficiently broad to
protect the Company's technology, that any patents issued to the Company will
not be sustained if challenged in court proceedings or otherwise or that third
parties will be able to develop products or processes that do not infringe
valid patents owned or licensed by the Company; and other risks detailed from
time-to-time in the Company's filings with the United States Securities and
Exchange Commission and Canadian securities authorities. The Company does not
assume any obligation to update any forward-looking statement.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION
CONTAINED HEREIN
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/128163.html
CONTACT:
Trudy Chimko, Human Resources & Corporate
Communications of AltaRex Corp., +1-781-672-0138,
investor@altarex.com
|
